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Introduction
The increasing prevalence of type 2 diabetes mellitus (T2DM) 
calls for developing concomitant screening strategies for early 
identification of high-risk individuals for the disease and/or 
its complications.1 The condition is comorbid with microvas-
cular disorders such as retinopathy and neuropathy. While 
glucose and insulin are the most well-established biomarkers, 
advances in the “omics” technologies have identified a range 
of molecules including genetic variants, proteins, RNA tran-
scripts, and small metabolites that could serve as predictors of 
diabetes risk.2
The natural history of T2DM suggests that the condi-
tion develops insidiously through periods of increased insu-
lin secretion, insulin resistance, impaired glucose tolerance, 
and cell dysfunction. Several independent hypothesis-driven 
studies have investigated single or panels of biomarkers to 
establish T2DM risk scores.3,4 Long-term population-based 
studies have shown that biomarker trajectories along the 
course of T2DM development diverge over time. For exam-
ple, decreased insulin sensitivity and increased interleukin-1 
(IL-1) receptor antagonist in serum are evident as early as 
13 and 6 years, respectively, prior to clinical diabetes.5,6 This 
suggests that repeated measures of diabetes-related variables 
will increase the predictive ability of diabetes risk scores.
Monitoring of serological parameters of diabetes typically 
involves invasive techniques with associated pain and distress. 
Hence, the development of noninvasive methods for frequent 
monitoring of biomarkers is a growing area of research. Some 
of the alternative methods evaluated include assessing skin 
auto-fluorescence for accumulation of advanced glycation end 
products and measuring the analytes in exhaled breath, urine, 
or saliva.7–10 Human saliva is a rich reservoir of analytes, com-
prising nearly 3,000 proteins and 12,000 peptides, and shares 
nearly 30% of proteins and 10% of peptides with the serum 
proteome and peptidome, respectively.11,12
Alterations in the salivary flow and composition in diabe-
tes are well documented.8,13,14 Salivary glucose is increased in 
T2DM.14 Salivary immunoreactive insulin level has been cor-
related with plasma insulin level after a glucose load in individ-
uals with normal glucose tolerance and in T2DM patients.15 
Although the mechanism of manipulation of salivary content 
by systemic diseases is not fully understood, it is suggested that 
the circulating biomolecules can reach the saliva by active (eg, 
sIgA) or passive (eg, steroids) transportation, or ultrafiltration 
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(eg, creatinine), or from the gingival crevicular fluid (GCF – a 
plasma filtrate arising from the junction between the sulcular 
epithelium and the tooth surface).16
In recent years, text mining methods are increasingly used 
to identify T2DM-specific risk factors from the vast clinical 
and experimental data in diabetes research.8,17 Based on the 
similarities between the serum and salivary proteomes, we 
hypothesized that the salivary proteome is likely to include a 
significant cohort of T2DM-specific serum proteins. We used 
the closed method of literature-based discovery to identify the 
presence in saliva of serum proteins that are correlated with 
the pathophysiological processes of T2DM.9,10,18 The abil-
ity to predict and identify disease occurrence/progression by 
biomarker panels is known to increase by including proteins 
of more than one pathological pathway.19 We evaluated select 
inflammatory mediators, adipokines, and ghrelin in diabetic 
saliva to validate our strategy for the identification of disease-
specific salivary biomarkers.
Methods
database mining. The PubMed database was serially 
interrogated using specific medical subject heading (MeSH) 
terms representing the primary sets of interest (P1, P2, and P3) 
and the secondary sets of interest (S1, S2, etc), resulting in the 
identification of common sets of interest (C1, C2, etc) (Fig. 1A). 
The MeSH includes terms that best reflect the article content as 
assigned by expert indexers at the National Library of Medicine 
(NLM).10 All English language publications in the PubMed 
database until January 30, 2014, was included. The MeSH 
terms insulin resistance, glucose intolerance, and insulin-
secreting cells, representing critical processes/components in 
the pathogenesis of T2DM, constituted the P1, P2, and P3 
primary sets, respectively. The three sets were then limited to 
diabetes mellitus, type 2 (MeSH), and proteins (MeSH), and 
filtered for humans. Each of the restricted primary set was 
then separately searched for the text word “serum” or “plasma”. 
The secondary sets consisted of factors and conditions inte-
grally associated with the development of insulin resistance, 
glucose intolerance, or impaired β-cell function,9,20 and 
included the following MeSH terms: lipids/blood, inflamma-
tion mediators, adipokines, obesity, glycoproteins, oxidative 
stress, blood coagulation factors, iron-binding proteins, anti-
bodies and globulins, and endothelium. Each secondary set 
was individually searched against each restricted primary set. 
S1–10 × (P1 + P2 + P3) constituted 10 common sets (C1–C10). 
Duplicate articles in the cumulative C1–C10 cohorts were 
removed. All retrospective, prospective, cross-sectional, 
and population studies were included for evaluation. The 
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figure 1. T2DM-specific circulating protein markers. (a) Literature-based search of the PubMed database for identifying T2DM-specific serum proteins 
using the mesh terms insulin resistance (P1) or glucose intolerance (P2), or insulin secreting cells (P3) and each of the 10 secondary sets is shown. [s1: 
lipids/blood, s2: obesity, s3: adipokines, s4: antibodies and globulins, s5: glycoproteins, s6: blood, coagulation factors, s7: inflammation mediators, S8: 
oxidative stress, s9: endothelium, and s10: iron-binding proteins]. the s1–10 × (P1 + P2 + P3) constitute the 10 common sets C1–C10. (B) Flow diagram of 
the search strategy for identification of T2DM-associated circulating protein biomarkers reported in saliva. The PubMed database was searched for saliva 
(MeSH) and blood proteins, the cohort being filtered for humans and English language. The articles in the retrieved cohort were searched for circulating 
biomarkers identified in (a) and manually screened for quantitation in saliva. The publication cohort of T2DM-specific circulating protein biomarkers 
reported in saliva was further divided into two groups based on articles reporting quantitation in t2Dm saliva (diabetic saliva) or other conditions 
(nondiabetic saliva).
records so retrieved were screened for the inclusion criteria of 
measurements of 1) fasting blood glucose/OGTT, 2) glycosy-
lated hemoglobin (HbA1c), 3) serum insulin, and 4) insulin 
sensitivity or insulin resistance index.3,6 All articles that satis-
fied three of the four criteria were then searched for names of 
protein markers and statistical significance. The resultant cohort 
obtained by this reductionist approach consisted of a total of 
297 articles. Articles reporting cellular and/or tissue biomarkers 
alone and/or qualitative assessments of proteins were excluded. 
Each marker was counted once irrespective of the number of 
publications. The identified markers were then classified into six 
distinct functional groups: Group I: lipids and enzymes; Group 
II: inflammatory mediators; Group III: adipokines; Group IV: 
vascular and coagulation factors; Group V: gut hormones and 
glucose homeostasis; and Group VI: oxidative stress.
Next we searched for reports of T2DM-associated serum 
proteins in saliva. The initial step consisted in retrieving articles 
reporting the presence of blood proteins in whole saliva using 
the MeSH term “saliva” and the text retrieval for “blood pro-
teins”. The retrieved cohort was filtered for English language 
and humans. After excluding review articles, the cohort of 
articles reporting blood proteins in saliva was searched for the 
measurement of each of the identified T2DM-associated cir-
culating protein biomarker. The retrieved articles were then 
manually screened for absolute measurement (not qualitative 
presence or relative/fold increase) of the markers and statis-
tical significance. The publication cohort of T2DM-specific 
circulating proteins reported to be present in saliva was fur-
ther divided into two groups based on measurement in T2DM 
saliva (diabetic saliva or DS) or other conditions (nondiabetic 
saliva or NDS). Each marker was counted once irrespective 
of the number of publications and the type of saliva (DS or 
NDS) (Fig. 1B). All searches and manual curation were per-
formed independently by two faculty members and two student 
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investigators. The retrieved information was assessed for simi-
larity. In case of discrepancies, all four individuals repeated 
the search and consensus was reached after discussion.
enzyme-linked immunosorbent assay (eLIsA). 
Unstimulated whole saliva (UWS) was collected into a pre-
chilled centrifuge tube by the drooling method21,22 from 20 
subjects with self-reported T2DM and HbA1c values (within 
the past 3 months) and 20 systemically healthy individuals 
attending the clinics of the Indiana University School of Den-
tistry (IUSD). Informed consent was obtained from all sub-
jects in accordance with the Indiana University’s Institutional 
Review Board (IRB). Each sample was clarified by centrifug-
ing at 4000g at 4 °C for 10 minutes and stored in the Complete 
Protease Inhibitor Cocktail (Roche) at –80 °C. All samples 
were depleted of amylase and immunoglobulins by incubat-
ing serially with antihuman amylase mAb (1:2500, cat. no. 
ab8944; Abcam) and protein G beads (Miltenyi Biotec Inc.) at 
4 °C. Total protein of the precleaned saliva samples was deter-
mined by spectrophotometry. One microgram of protein from 
each precleaned UWS sample was assessed for the presence of 
IL-6/TNF-α (tumor necrosis factor α)/resistin/visfatin/ghre-
lin. The salivary resistin, visfatin, and ghrelin were determined 
using specific colorimetric kits following the manufacturer’s 
instructions (Cayman Chemical Company). IL-6 and TNF-α 
concentration in the saliva were determined using OptELISA 
kits (BD Biosciences).
statistical analysis. The differences in the analyzed sol-
uble proteins in UWS of normal and T2DM subjects were 
determined by Student’s t-test. P-Values 0.05 were consid-
ered significant.
results
compilation of serum proteins reported as markers 
for t2dM in PubMed. A total of 53,373, 7,851, and 6,119 
articles were retrieved in the P1, P2, and P3 primary sets, 
respectively. Refining for T2DM and serum/plasma proteins 
and filtering for humans retrieved 1,867 (3.5%), 330 (4.2%), 
and 174 (2.8%) publications for each of the P1, P2, and P3 sets, 
respectively (Fig. 1A). When combined, the P1 × P2 cohort 
had 111 duplicate records, P1 × P3 cohort had 64 duplicates, 
and the P1 × P2 × P3 cohort had 7 duplicates. This suggested 
that .50% of articles were unique to each primary set and 
that the insulin resistance is a frequently used MeSH term in 
T2DM studies. Although the concepts of obesity, adipokines, 
and lipids/blood are highly related, each concept retrieved 
different sets of articles and shared only 8.9% of the articles. 
Therefore, to avoid missing information in the nonduplicate 
articles, the subsets were independently searched against each 
primary set. A total of 588 unique articles in the cumulative 
C1–C10 cohort were then manually curated for inclusion of 
well-accepted criteria of T2DM diagnosis, such as measures 
of fasting blood glucose/OGTT (oral glucose tolerance test), 
HbA1c, and insulin sensitivity/resistance. The resultant cohort 
of 297 articles (19.8%) was then screened for quantitative 
assessment of protein markers. A total of 214 proteins were 
identified, which were classified into six distinct functional 
groups as related to the processes of glucose and lipid metabo-
lism, energy homeostasis, inflammation, endothelial perturba-
tion, adipocyte activation, and oxidative stress. The number of 
circulating T2DM proteins ranged between 25 and 47 mark-
ers per functional group. Markers such as plasma insulin and 
glucose that belong to Group V have been evaluated in most 
studies as essential indicators of T2DM, while others such as 
vasculin or progranulin that belong to Group IV have been 
reported in isolated studies (Fig. 2A). Although the level of 
confidence was not determined, the inclusion of articles lim-
ited to those reporting statistical difference between the nor-
mal and T2DM samples supports the efficacy of association of 
the compiled markers with T2DM.
Identification of t2dM-associated serum proteins 
reported in saliva in PubMed. All identified serum/plasma 
T2DM markers were individually searched for quantitative 
assessment in saliva (Fig. 1B). Of the 214 circulating protein 
markers, 130 (60%) have been measured in saliva (Supplemen-
tary Table 1). While the inflammatory mediators (Group II), 
adipokines (Group III), and markers of oxidative stress (Group 
VI) represent the most investigated, vascular and coagula-
tion factors (Group IV) represent the least evaluated group 
of T2DM serum proteins in human saliva (Fig. 2B). When 
screened for assessment in diabetes, it was observed that only 
62 of the 130 salivary markers have been specifically mea-
sured in T2DM saliva, with the remaining being determined 
in other conditions including but not restricted to Sjogren’s 
syndrome or periodontitis. The number of markers assessed in 
diabetic and nondiabetic saliva per functional group is given 
in Figure 2C. It is important to note that, since most studies 
used control saliva samples, all 130 T2DM-associated protein 
markers with the exception of glutamic acid decarboxylase 
antibody can be measured in healthy saliva. Since the com-
piled cohort was restricted to quantitatively assessed markers, 
it is envisioned that, similar to circulating C-reactive protein 
and other serum markers for T2DM, differences in the con-
centration of select proteins between diabetic and nondiabetic 
saliva can be of diagnostic and/or prognostic significance.
Measurement of t2dM-associated serum protein 
markers in diabetic saliva. Assessment of multiple mark-
ers derived from different pathways of the disease pathogen-
esis is likely to exhibit greater potential for risk prediction 
of complex progressive diseases such as T2DM.19 The criti-
cal role of inflammation potentially initiated by changes in 
the adipose tissue is increasingly recognized as pivotal to the 
pathogenesis of T2DM.9,23 Gut hormones (Group IV) such 
as ghrelin regulate glucose homeostasis and exert antioxidant 
and anti-apoptotic effects, thereby playing a role in prevent-
ing diabetic complications such as nephropathy.24 Hence, as 
proof of concept of our data mining method and the infor-
mation retrieved, we assessed representative inflammatory 
mediators from Group II (TNF-α and IL-6), adipokines 
Salivary biomarkers diabetes mellitus
43Biomarker insights 2015:10
detection of the less abundant adipokines and ghrelin. While 
the concentration of TNF-α was significantly lower, that of 
IL-6 was significantly higher in T2DM saliva as compared to 
that in healthy saliva samples (Table 1). The salivary levels of 
acylated and deacylated ghrelin were slightly higher in T2DM 
saliva than in control saliva, although the difference was not 
significant (Table 1). Significantly decreased levels of ghrelin 
in the saliva of T2DM patients have been reported earlier.25 
The differences in the salivary ghrelin levels in our study could 
be attributed to the nature of the sample (whole saliva vs pre-
cleaned) and the differences in the methods (ELISA vs radio-
immunoassay/fast protein liquid chromatography) used. With 
respect to the adipokines, while the concentration of visfatin 
was significantly higher in T2DM saliva, that of resistin was 
equivalent to that in control samples (Table 1). The presence 
of resistin in saliva is at about half the concentration in serum 
and elevated levels in T2DM saliva has been reported ear-
lier.26,27 The observed discrepancy could be due to the differ-
ences in the nature of the sample (whole saliva vs precleaned) 
and potentially the duration of diabetic status, since salivary 
resistin has been correlated with homeostatic model assess-
ment (HOMA)-insulin resistance.27
discussion
Discriminatory salivary biomarkers for systemic diseases such 
as breast, lung, and pancreatic cancers have been successfully 
identified and prevalidated.16,28 In this literature-based discov-
ery, using T2DM serum proteome as the source, we identified 
a panel of 130 salivary proteins with potential for noninvasive 
risk assessment of T2DM. These include constituents that 
enter saliva from plasma and those that are secreted by the 
salivary glands. It has been suggested that the increased base-
ment membrane permeability often associated with diabetes is 
a potential mechanism for increased passage of proteins and 
metabolites from the exocrine glands and for the enhanced 
leakage of serum-derived components into whole saliva.15
A significant concern regarding the use of salivary 
biomarkers for systemic diseases is the reliability for clini-
cal application. While large proteins such as cytokines that 
reach saliva from crevicular fluid or via leaky passage from 
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figure 2. (a) Functional classification of the T2DM-associated circulating 
protein markers reported in the PubMed database. The T2DM-specific 
circulating proteins identified as in Figure 1A were classified into six 
functional groups. Group I: lipids and enzymes, Group II: inflammatory 
mediators, group iii: adipokines, group iV: vascular and coagulation 
factors, group V: gut hormones and glucose homeostasis, and group Vi: 
oxidative stress. (a) shows the total number of markers reported in each 
group. (B, C) Classification of T2DM specific circulating protein markers 
reported in saliva. the Pubmed database was searched for reports 
of blood proteins (see text) in saliva (MeSH) and filtered for humans 
and english language. after excluding review articles, the retrieved 
cohort was screened for each of the 214 t2Dm-associated circulating 
markers. each marker was counted once irrespective of the number of 
publications. (B) shows the percentage of t2Dm markers reported to 
be measured in human saliva in each group. the publication cohort of 
T2DM-specific serum proteins reported in saliva was further divided into 
two groups based on measurement in t2Dm saliva (diabetic saliva or Ds) 
or other condition (nondiabetic saliva or nDs). (C) shows the number of 
markers of each group reported to be measured in Ds and nDs.
from Group III (resistin and visfatin), and gut hormone from 
Group IV (acylated ghrelin and deacylated ghrelin) in diabetic 
saliva. We depleted the saliva samples of the abundant high-
molecular-weight amylase and immunoglobulins to improve 
Table 1. salivary markers in t2Dm.
MaRkeRS T2DM ConTRoL p vaLue
tnF-α 19.1 ± 5.2 pg/ml 28.6 ± 12.5 pg/ml #0.015*
iL6 69.3 ± 18.6 pg/ml 53 ± 20.3 pg/ml #0.03*
acylated ghrelin 12.5 ± 0.5 pg/ml 7.9 ± 1.8 pg/ml #0.076
Deacylated ghrelin 10.7 ± 4.7 pg/ml 8.1 ± 1.9 pg/ml #0.061
resistin 116.9 ± 98.6 pg/ml 67.2 ± 27.1 pg/ml #0.103
Visfatin 30.5 ± 5.12 pg/ml 12.2 ± 5.6 pg/ml #0.004*
notes: Unstimulated whole saliva (UWs) from 20 t2Dm and 20 healthy saliva 
samples were assessed for the indicated marker by eLisa. Data given as 
mean ± sD. *P  0.05.
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inflamed tissue are less likely to exhibit reliable saliva plasma 
ratio, small apolar molecules such as cortisol or low-density 
lipoproteins can diffuse efficiently and exhibit consistent saliva 
plasma ratio for reliable measurements.29 A few reports have 
correlated salivary markers with HbA1C levels – a measure 
of average serum glucose concentration – and hence indi-
rectly with glycemic control. For example, salivary IL-6 or 1,5 
anhydroglycitol has been positively correlated with HbA1c in 
T2DM.4,30 Salivary sex hormone binding globulin (SHBG) 
has been correlated negatively with HOMA-insulin resistance 
in nondiabetic, postmenopausal, obese women.7 Our compre-
hensive search of the published literature showed that, while 
48% of T2DM-associated serum proteins have been assessed 
in diabetic saliva, 52% of the T2DM serum proteins were 
measured in nondiabetic saliva.
Our study has two limitations. First, the data are 
restricted to articles retrieved from the PubMed database, 
thereby potentially missing reports that might have been 
captured by including additional databases such as Embase 
and Science Citation Index. Second, the search included all 
articles reporting quantitation of proteins irrespective of the 
presence/absence of oral/systemic pathologies that might be 
related causally or otherwise to specific salivary protein(s). 
While this may be perceived as a potential drawback,31,32 since 
the search of salivary markers was restricted to serum proteins 
associated with T2DM pathophysiology, it is very likely that 
the identified salivary proteins will have considerable value as 
risk predictors of T2DM.
Evaluation of proteins from different functional classes 
is an acceptable alternative strategy to improve predic-
tive ability. Assessment of select panels of serum biomark-
ers such as TNF-α, IL-6, E-selectin, soluble intercellular 
cell adhesion molecule-1 (sICAM-1), and soluble vascular 
cell adhesion molecule-1 (sVCAM-1) or adiponectin, leptin, 
monocyte chemoattractant protein-1, E-selectin, sICAM-1, 
and sVCAM-1 have been shown to significantly improve inte-
grated discrimination and risk prediction of T2DM, albeit 
marginally over the classical risk factors.33–36 In the context of 
salivary markers for T2DM, the frequent prevalence of con-
comitant chronic periodontitis could potentially compromise 
the clinical significance.30–32 For example, elevated cytokines 
(TNF-α and IL-6) in saliva have been reported in chronic 
periodontitis with or without diabetes.30,31 Similarly, increased 
visfatin in the GCF has been reported in chronic periodontitis 
with or without diabetes.37 Increased resistin in the GCF has 
been observed in chronic periodontitis, more significantly in 
chronic periodontitis with T2DM.38 Thus, since chronic peri-
odontitis represents a common confounding factor in diabetes, 
inclusion of markers that differentiate the cumulative effects 
of T2DM with periodontitis and T2DM alone either qualita-
tively or quantitatively will enhance the predictive power of a 
biomarker panel. In a recent review, Sattar suggested that the 
potential for clinical use of biomarkers is highest in diabetic 
complications.9 In this context, it is pertinent to note that many 
inflammatory and immune-associated proteins determined in 
saliva have been reported as potential biomarkers for diabetic 
retinopathy.9
In conclusion, we observed that, in addition to the previ-
ously reported 61 proteins, there are at least 84 distinct, quan-
tifiable salivary proteins that have not been assessed in diabetic 
saliva. Since the risk factors are predictive over time, periodic 
assessment is of critical significance. Saliva represents a non-
invasive biospecimen for frequent measurement of markers, 
facilitating early detection and improved strategies for diabe-
tes prevention and management. In addition, the greater ease 
of testing special populations of patients (eg, confined, remote, 
pediatric) makes assessment of salivary biomarkers an attrac-
tive social and cost-effective strategy. However, despite the 
considerable excitement generated, caution must be exercised 
since the type of sample (stimulated/unstimulated; whole/
glandular saliva), circadian variations, and susceptibility to 
preprocessing are some of the confounding parameters that 
should be addressed in biomarker selection and validation.39
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